504 related articles for article (PubMed ID: 28362071)
41. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
42. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys EH; Chang LW; Harris J
Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
[TBL] [Abstract][Full Text] [Related]
43. The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages.
Missailidis C; Neogi U; Stenvinkel P; Trøseid M; Nowak P; Bergman P
AIDS; 2018 Jul; 32(12):1589-1598. PubMed ID: 29620717
[TBL] [Abstract][Full Text] [Related]
44. Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
Zuccotti G; Viganò A; Gabiano C; Giacomet V; Mignone F; Stucchi S; Manfredini V; Marinacci F; Mora S
Bone; 2010 Jun; 46(6):1633-8. PubMed ID: 20211284
[TBL] [Abstract][Full Text] [Related]
45. Expression of gut-homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV-1-infected patients?
Abad-Fernández M; Gutiérrez C; Madrid N; Hernández-Novoa B; Díaz L; Muñoz-Fernández MA; Moreno S; Vallejo A
HIV Med; 2015 Jan; 16(1):15-23. PubMed ID: 24831847
[TBL] [Abstract][Full Text] [Related]
46. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Integrase Strand Transfer Inhibitors (INSTIs) and Protease-Boosted Inhibitors (PIs) on the Reduction in Chronic Immune Activation in a Virally Suppressed, Mainly Male Population Living with HIV (PLWH).
Nitsotolis T; Kyriakoulis KG; Kollias A; Papalexandrou A; Kalampoka H; Mastrogianni E; Basoulis D; Psichogiou M
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399618
[No Abstract] [Full Text] [Related]
48. Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression.
Basilissi M; Tincati C; Merlini E; Ancona G; Borghi E; Borgo F; Barassi A; d'Arminio Monforte A; Marchetti G
PLoS One; 2019; 14(2):e0212075. PubMed ID: 30763359
[TBL] [Abstract][Full Text] [Related]
49. Characterization of gut microbiota composition in HIV-infected patients with metabolic syndrome.
Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
J Physiol Biochem; 2019 Aug; 75(3):299-309. PubMed ID: 30924020
[TBL] [Abstract][Full Text] [Related]
50. Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota.
Deusch S; Serrano-Villar S; Rojo D; Martínez-Martínez M; Bargiela R; Vázquez-Castellanos JF; Sainz T; Barbas C; Moya A; Moreno S; Gosalbes MJ; Estrada V; Seifert J; Ferrer M
AIDS; 2018 Jun; 32(10):1229-1237. PubMed ID: 29683848
[TBL] [Abstract][Full Text] [Related]
51. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kryst J; Kawalec P; Pilc A
PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
[TBL] [Abstract][Full Text] [Related]
52. Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation.
Volpe GE; Ward H; Mwamburi M; Dinh D; Bhalchandra S; Wanke C; Kane AV
J Stud Alcohol Drugs; 2014 Mar; 75(2):347-57. PubMed ID: 24650829
[TBL] [Abstract][Full Text] [Related]
53. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.
Pérez-Santiago J; Gianella S; Massanella M; Spina CA; Karris MY; Var SR; Patel D; Jordan PS; Young JA; Little SJ; Richman DD; Smith DM
AIDS; 2013 Jul; 27(12):1921-31. PubMed ID: 24180001
[TBL] [Abstract][Full Text] [Related]
54. Impact of HIV infection and integrase strand transfer inhibitors-based treatment on the gut virome.
Villoslada-Blanco P; Pérez-Matute P; Íñiguez M; Recio-Fernández E; Jansen D; De Coninck L; Close L; Blanco-Navarrete P; Metola L; Ibarra V; Alba J; Matthijnssens J; Oteo JA
Sci Rep; 2022 Dec; 12(1):21658. PubMed ID: 36522388
[TBL] [Abstract][Full Text] [Related]
55. Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.
Kim CJ; Walmsley SL; Raboud JM; Kovacs C; Coburn B; Rousseau R; Reinhard R; Rosenes R; Kaul R
HIV Clin Trials; 2016 Jul; 17(4):147-57. PubMed ID: 27267710
[TBL] [Abstract][Full Text] [Related]
56. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection.
Tincati C; Douek DC; Marchetti G
AIDS Res Ther; 2016; 13():19. PubMed ID: 27073405
[TBL] [Abstract][Full Text] [Related]
57. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
58. [Anti-HIV drugs].
Koibuchi T
Uirusu; 2013; 63(2):199-208. PubMed ID: 25366054
[TBL] [Abstract][Full Text] [Related]
59. Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.
Mudd JC; Brenchley JM
J Infect Dis; 2016 Oct; 214 Suppl 2(Suppl 2):S58-66. PubMed ID: 27625432
[TBL] [Abstract][Full Text] [Related]
60. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
